H.C. Wainwright raised the firm’s price target on Exelixis (EXEL) to $54 from $52 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q4 report.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Arcus Biosciences downgraded to Equal Weight from Overweight at Wells Fargo
- Exelixis Earnings Call: CABOMETYX Strength, ZANZA Catalyst
- Exelixis price target raised to $44 from $43 at Stifel
- Exelixis: Solid Q4 Execution and Advancing Pipeline Underpin Buy Rating and 2026 Earnings Power
- Exelixis reports Q4 EPS 94c, consensus 81c